Hospital
North Platte Nebraska Hospital Corporation
North Platte Nebraska Hospital Corporation was paid $16.36M by Medicaid between Jan 2018 and Dec 2024, across 253 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 17% of everything it billed.
33Billing provider infoNORTH PLATTE NEBRASKA HOSPITAL CORPORATION
NORTH PLATTE, NE 69101
NORTH PLATTE, NE 69101
33aNPI1700855533assigned 03/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.36M
24GClaims372,444
24DCodes billed253
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nebraska
Rank by total paid#1 of 8
Median peer was paid$1.62M
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,547 | $1.77M | |
| 2019 | 43,954 | $1.50M | |
| 2020 | 48,061 | $2.23M | |
| 2021 | 79,191 | $3.29M | |
| 2022 | 93,053 | $3.94M | |
| 2023 | 45,366 | $2.27M | |
| 2024incomplete | 20,272 | $1.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 17% | 43,125 | 31,969 | $2.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 16,954 | 15,316 | $2.44M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.9% | 16,412 | 4,568 | $1.29M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.4% | 7,401 | 1,491 | $716K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.2% | 7,556 | 6,165 | $689K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.2% | 7,940 | 1,785 | $682K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 1,764 | 1,629 | $635K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 4,486 | 4,265 | $631K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.8% | 5,295 | 4,795 | $627K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.5% | 2,352 | 1,876 | $572K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 4,184 | 2,656 | $468K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.3% | 1,506 | 1,433 | $371K |
241 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,615 | $356K |
| G0378 | Hospital observation service, per hour | 1.8% | 1,830 | $302K |
| 99285 | Emergency room visit (most serious) | 1.1% | 1,242 | $173K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 822 | $168K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,168 | $163K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 477 | $162K |
| 20610 | <1% | 731 | $133K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,362 | $121K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,567 | $114K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,230 | $96K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,147 | $89K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,626 | $87K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,845 | $86K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 286 | $85K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 136 | $81K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,402 | $80K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 512 | $72K |
| 80053 | Comprehensive metabolic panel | <1% | 17,725 | $71K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 230 | $70K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 522 | $68K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,402 | $64K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,220 | $64K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 137 | $59K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 229 | $56K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 486 | $56K |
| J3490 | Unclassified drugs | <1% | 16,500 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,431 | $54K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,604 | $52K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 528 | $52K |
| 97113 | <1% | 497 | $51K | |
| 97162 | <1% | 1,128 | $48K | |
| 97166 | <1% | 330 | $40K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 524 | $39K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 84 | $39K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,973 | $38K |
| 93017 | <1% | 163 | $36K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,307 | $35K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 318 | $33K |
| 20553 | <1% | 140 | $32K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 176 | $32K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 865 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,353 | $30K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $28K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,970 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,438 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,859 | $22K |
| 64615 | <1% | 75 | $21K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 7,087 | $20K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 976 | $19K |
| 95886 | <1% | 96 | $18K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $17K |
| 97161 | <1% | 873 | $17K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 723 | $16K |
| 90670 | <1% | 219 | $16K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 20 | $15K |
| 94729 | <1% | 630 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,520 | $14K |
| A9270 | Non-covered item or service | <1% | 1,961 | $13K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,058 | $12K |
| 94010 | <1% | 273 | $12K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 281 | $11K |
| 97014 | <1% | 253 | $11K | |
| 97760 | <1% | 190 | $11K | |
| 94060 | <1% | 288 | $11K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 52 | $10K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 82 | $10K |
| 83880 | <1% | 1,022 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,760 | $10K |
| 87070 | <1% | 1,418 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,156 | $9K |
| 86850 | <1% | 1,098 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 275 | $9K |
| 86900 | <1% | 1,204 | $9K | |
| 84484 | <1% | 2,996 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,978 | $8K |
| 87186 | <1% | 1,649 | $8K | |
| 81001 | <1% | 5,852 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 288 | $8K |
| 73610 | <1% | 429 | $8K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 841 | $8K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 9,079 | $8K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 122 | $8K |
| 93971 | <1% | 81 | $8K | |
| 80061 | Lipid panel | <1% | 1,450 | $8K |
| 62323 | <1% | 13 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,055 | $7K |
| 83735 | <1% | 3,455 | $7K | |
| 83605 | <1% | 2,499 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,244 | $7K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 298 | $6K |
| 84703 | <1% | 2,218 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,578 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 183 | $5K |
| 0099U | <1% | 46 | $5K | |
| 73030 | <1% | 453 | $5K | |
| 90651 | <1% | 29 | $5K | |
| 83690 | <1% | 2,325 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 387 | $5K |
| 59025 | Fetal non-stress test | <1% | 51 | $5K |
| 87088 | <1% | 1,180 | $4K | |
| 90681 | <1% | 111 | $4K | |
| 82962 | <1% | 3,843 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 285 | $4K |
| 85027 | <1% | 1,141 | $4K | |
| 97597 | <1% | 36 | $4K | |
| 84439 | <1% | 439 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 664 | $4K |
| 73630 | <1% | 189 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,926 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,271 | $4K |
| 81003 | <1% | 994 | $4K | |
| 97803 | <1% | 283 | $4K | |
| 82803 | <1% | 852 | $3K | |
| 90686 | <1% | 528 | $3K | |
| 86140 | <1% | 723 | $3K | |
| 90723 | <1% | 158 | $3K | |
| 97035 | <1% | 23 | $3K | |
| 82553 | <1% | 839 | $3K | |
| 73130 | <1% | 261 | $3K | |
| 90647 | <1% | 141 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 119 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 795 | $3K |
| 94726 | <1% | 130 | $3K | |
| 90716 | <1% | 32 | $3K | |
| 82550 | <1% | 1,266 | $3K | |
| 71250 | <1% | 27 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 43 | $3K |
| 90707 | <1% | 39 | $2K | |
| 76536 | <1% | 12 | $2K | |
| 72141 | <1% | 15 | $2K | |
| 95885 | <1% | 12 | $2K | |
| 74018 | <1% | 70 | $2K | |
| 20552 | <1% | 14 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 25 | $2K |
| 83655 | <1% | 130 | $2K | |
| 96367 | <1% | 37 | $2K | |
| 94664 | <1% | 75 | $2K | |
| 73221 | <1% | 13 | $2K | |
| 87205 | <1% | 872 | $2K | |
| 87077 | <1% | 477 | $2K | |
| 96376 | <1% | 147 | $2K | |
| 93299 | <1% | 119 | $2K | |
| 90461 | <1% | 86 | $2K | |
| 85610 | <1% | 1,557 | $2K | |
| 73560 | <1% | 119 | $2K | |
| 97802 | <1% | 55 | $2K | |
| 90696 | <1% | 41 | $2K | |
| 0097U | <1% | 12 | $2K | |
| 82607 | <1% | 206 | $2K | |
| 82728 | <1% | 372 | $2K | |
| 86901 | <1% | 1,164 | $2K | |
| 87040 | <1% | 662 | $2K | |
| 73562 | <1% | 295 | $2K | |
| 87081 | <1% | 208 | $2K | |
| 36000 | <1% | 43 | $1K | |
| 36591 | <1% | 482 | $1K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 14 | $1K |
| 85379 | <1% | 716 | $1K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 14 | $1K |
| 72110 | <1% | 26 | $1K | |
| 29125 | <1% | 56 | $1K | |
| 73110 | <1% | 110 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 784 | $1K |
| 70486 | <1% | 12 | $1K | |
| 94644 | <1% | 15 | $973.80 | |
| 51798 | <1% | 84 | $932.57 | |
| 83540 | <1% | 330 | $895.95 | |
| 73502 | <1% | 46 | $861.18 | |
| 80329 | <1% | 198 | $831.60 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 666 | $816.17 |
| 83550 | <1% | 275 | $770.09 | |
| 84145 | <1% | 582 | $761.99 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 267 | $757.92 |
| 73100 | <1% | 32 | $749.36 | |
| 80050 | General health panel | <1% | 18 | $741.54 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 46 | $710.79 |
| 85652 | <1% | 443 | $660.13 | |
| 90633 | <1% | 41 | $641.20 | |
| 94761 | <1% | 1,145 | $589.37 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 18 | $536.04 |
| 83525 | <1% | 38 | $492.51 | |
| 12001 | <1% | 12 | $435.49 | |
| 85730 | <1% | 104 | $430.64 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $414.30 |
| 90734 | <1% | 16 | $388.44 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 49 | $379.57 |
| 97116 | <1% | 27 | $351.83 | |
| 73564 | <1% | 16 | $322.18 | |
| 85018 | <1% | 87 | $254.91 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15 | $231.77 |
| 84702 | <1% | 44 | $200.38 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 301 | $188.22 |
| 99152 | <1% | 87 | $176.99 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 386 | $149.90 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 25 | $143.23 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 35 | $126.50 |
| 82540 | <1% | 28 | $110.55 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 15 | $107.12 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 736 | $106.53 |
| G0008 | Administration of influenza virus vaccine | <1% | 96 | $103.65 |
| 94760 | <1% | 284 | $93.36 | |
| 99156 | <1% | 81 | $76.44 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 25 | $75.90 |
| 80069 | <1% | 15 | $60.60 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 2,147 | $47.64 |
| 99153 | Mod sedat endo service >5yrs | <1% | 16 | $38.99 |
| 99157 | <1% | 61 | $38.22 | |
| 86200 | <1% | 15 | $32.84 | |
| 84100 | <1% | 15 | $25.82 | |
| 82565 | <1% | 16 | $25.73 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 327 | $23.18 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 279 | $18.15 |
| 80320 | <1% | 43 | $16.27 | |
| 82784 | <1% | 12 | $11.79 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,771 | $11.68 |
| 36592 | <1% | 74 | $6.58 | |
| 86803 | <1% | 12 | $1.51 | |
| 83615 | <1% | 27 | $0.56 | |
| C1769 | Guide wire | 0% | 134 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 134 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 137 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 91 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 14 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 26 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 17 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 16 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 15 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 378 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 61 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 135 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 281 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 119 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 120 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 68 | $0.00 |
| 80347 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 215 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 63 | $0.00 |
| 80326 | 0% | 12 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 33 | $0.00 |
| 80364 | 0% | 12 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOWEN, SUMMER (CFO)
| Provider | Location | Paid |
|---|---|---|
| North Platte Nebraska Hospital Corporation | North Platte, NE | $9.52M |
| North Platte Nebraska Hospital Corporation | North Platte, NE | $1.33M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.